Author’s response to reviews

Title: Characterization of Beta2-Microglobulin Expression in Different Types of Breast Cancer

Authors:

Kesheng Li (likesheng63@hotmail.com)
Huifen Du (shwjshzhx@163.com)
Xiaowen Lian (cijiale@163.com)
Suisheng Yang (13919820666@126.com)
Dandan Chai (chaidandan2006@163.com)
Chunya Wang (shwjshzhx@163.com)
Rong Yang (Yqq2000115@sohu.com)
Xuezhong Chen (Doctorcxz@eyou.com)

Version: 4  Date: 29 September 2014

Author’s response to reviews: see over
Dear Dr. Remoto:

On behalf of my co-authors, we thank you very much for your kind letter about the correction of our manuscript entitled “Characterization of β2-Microglobulin Expression in Different Types of Breast Cancer” (ID: 2073262619133320) for publication in “BMC Cancer”. We have studied reviewer’s comments carefully and have made correction which we hope meet with approval. Revised portion are marked in red in the paper. The main corrections in the manuscript and the responds to the reviewers’ comments are as follows:

**Reviewer 1:**

“Reviewer’s report: The authors have revised the manuscript as possible as they can do according to the comments. It may be acceptable for publication.”

“Quality of written English: Acceptable”

Thank you very much for the reviewer’s comments concerning our manuscript.

**Reviewer 2:**

“Reviewer’s report: The revision is adequate and acceptable but grammar and spell check is required before the manuscript can be published.”

“Quality of written English: Needs some language corrections before being published”
Page 3 Line 51, “using” was corrected as “by”.

Page 6 Line 120, “(Reference number: A201301310001)” was added.

Page 10 Line 197, “anti-β-Actin” was corrected as “anti-β-actin”.

Page 10 Line 198, “anti-Bcl2” was corrected as “anti-Bcl-2”.

Page 13 Line 256, “overexpression” was corrected as “Overexpression”.

Page 21 Line 432, “Epithelial” was corrected as “epithelial”.

Page 21 Line 433, “Mesenchymal Transition” was corrected as “mesenchymal transition”, and “Cancer Lethality” was corrected as “cancer lethality”.

Page 21 Line 434, “Human Cancer Cells” was corrected as “human cancer cells”.

Page 22 Line 460, “Survivin” was corrected as “survivin”.

Page 23 Line 474, “Metastasis” was corrected as “metastasis” in Table 1.

Page 25 Line 487, “P53” was corrected as “p53” in Table 7.

Special thanks to you for your good comments.

In addition, we are very sorry that we can’t provide you with a link to the homepage of the Medical Ethics Committee of Medicine and Science Research Institute of Gansu Province which approved our study, because the homepage has not been built so far. Nonetheless, this study has been approved by the Ethics Committee (Reference number: A201301310001).
We would like to express our great appreciation to you and reviewers for comments on our manuscript, and hope that the correction will meet with approval.

We look forward to hearing from you at your earliest convenience.

Yours sincerely,

Kesheng Li

Corresponding author:

Name: Kesheng Li

E-mail: Likesheng63@hotmail.com